Will Bausch + Lomb break free from debt-heavy Bausch Health? Sale rumours ignite market frenzy!
Bausch + Lomb saw its stock surge by 13% in Toronto, trading at 24.01 Canadian dollars (around $17.67), following a report by the Financial Times ... Read More
Bausch + Lomb completes XIIDRA acquisition to fortify dry eye offering
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a prominent global eye health company, has successfully wrapped up its acquisition of XIIDRA (lifitegrast ophthalmic solution) 5%. XIIDRA ... Read More
Bausch + Lomb acquires Johnson & Johnson Vision’s Blink product line
Bausch + Lomb, an esteemed global eye health company, has broadened its portfolio by purchasing Johnson & Johnson Vision's Blink product line for $106.5 million. ... Read More
Bausch + Lomb to acquire dry eye disease medication XIIDRA from Novartis
Bausch + Lomb has reached a definitive agreement with Novartis to acquire the non-steroid eye drop XIIDRA (lifitegrast ophthalmic solution) 5%, known for treating dry ... Read More